Across TCGA pan-cancer cohorts, ZNF33B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF33B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF33B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF33B expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where ZNF33B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	III,IV	1.000	0.536	.025	10	view →
PRAD	DFS	Median	All	0.085	0.774	.002	6	view →
SKCM	OS	Median	All	0.456	0.783	.048	3	view →
BLCA	DFS	Median	II,III,IV	0.897	0.607	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF33B tumor-vs-normal RNA expression · all ZNF33B data types